CD274 and small cell lung carcinoma: Atezolizumab is a recombinant humanized anti-PD-L1 monoclonal antibody that blocks interactions between PD-1 and its ligands, and previous clinical trials have reported that Atezolizumab achieved a good effect in ES-SCLC with few side effects (13).